Physician profile
Marc A Kovalchik
NPI 1871925842
$4,425.47
in general payments reported to CMS, 2019-2025
16 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 89% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $489 · 2022: $524 · 2023: $1,131 · 2024: $1,139 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,412.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.16 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $583.31 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $561.59 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $544.72 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $512.07 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $485.01 | 2021-2025 | Ingrezza |
| Bausch Health US, LLC | $364.06 | 2021-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $174.18 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $169.83 | 2021-2024 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $72.32 | 2022-2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $64.24 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $58.08 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $52.09 | 2024-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $50.02 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $47.52 | 2022-2025 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $24.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Kovalchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.